Argenx Se (NASDAQ: ARGX)
Argenx Se Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Argenx Se Company Info
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
News & Analysis
Is Argenx Stock a Buy Now?
Good news keeps rolling in for the biotech.
Why Shares of Argenx Jumped This Week
The company's lead therapy showed progress in treating an autoimmune disorder.
Why Argenx Stock Is On Fire Today
A major clinical win is boosting the drugmaker's shares today.
You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers
Big gains are afoot even as the markets prepare for a flat open.
This Emerging Market Could Be the Next Big Thing in Biotech
Medicines to treat the many symptoms of long COVID are in high demand already.
Is Argenx a Good Biotech Stock to Buy for 2022?
The recent approval of this drugmaker's first product is giving reasons to cheer now, but what about down the road?
Here's Why argenx Stock Is Soaring Today
Positive pivotal trial results are giving investors a reason to cheer.
These 3 European Biotechs Can Help Recession-Proof Your Portfolio
Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.